Key Drivers
- Margin Compression
- Higher Leverage
- Positive Cash Flow
AIAI Summary
Waters is now an integration-and-deleveraging execution story: sustained high-single-digit organic growth, $200M in BD synergies, and margin/FCF recovery must materialize quickly to justify its premium valuation and $5.45B debt load.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Compression
- •Higher Leverage
- •Positive Cash Flow
WAT's historically strong profitability and liquidity are now overshadowed by sharp margin compression, a quarterly loss, rising leverage, intangible-asset risk, and demanding valuation.
Price Behavior
Key Price Behavior Insights:
- •Higher trading range
- •Resistance rejection
- •Support test
WAT is cautiously bullish over the last month, but its pullback from $429.72 resistance favors watching $410–$414 support before adding exposure.
Pullback to $421.63 after testing $429.72 resistance
Sentiment & News
Key News Insights:
- •Share Momentum
- •Screening Partnerships
- •Instrument Launch
Waters' bullish share momentum, expanded cancer-screening partnerships, and new flow-cytometry launch support a positive growth outlook despite mixed institutional trading.
New healthcare partnerships and product commercialization could strengthen Waters' growth profile and investor sentiment
Similar Companies in Healthcare
Other companies in the same sector with AI ratings